Not applicableStudy completedNCT05572645What this trial is testingPyrotinib Plus Trastuzumab Versus Pertuzumab Plus TrastuzumabWho this might be right forBreast Cancer Fudan University 333
Post-approval studies (Phase 4)UnknownNCT05131841What this trial is testingCipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBCWho this might be right forMetastatic Breast Cancer Zhejiang Cancer Hospital 60
Early research (Phase 1)Study completedNCT01624441What this trial is testingDinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast CancerWho this might be right forEstrogen Receptor NegativeHER2/Neu NegativeMale Breast Carcinoma+4 more National Cancer Institute (NCI) 40
Testing effectiveness (Phase 2)UnknownNCT03919253What this trial is testingPyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory StudyWho this might be right forHER2-positive Breast Cancer Hebei Medical University Fourth Hospital 80
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05519670What this trial is testingA Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCErWho this might be right forBreast Cancer Institut Paoli-Calmettes 72
Testing effectiveness (Phase 2)Study completedNCT00191373What this trial is testingA Trial for HER2 Positive Breast Cancer Patients With Metastatic DiseaseWho this might be right forBreast NeoplasmsCancer of the BreastBreast Cancer Eli Lilly and Company 66
Large-scale testing (Phase 3)Active Not RecruitingNCT04565054What this trial is testingAdjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBCWho this might be right forBreast Cancer Female Women's Cancer Study Group GmbH 1,260
Not applicableNot Yet RecruitingNCT07480694What this trial is testingEribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With ADCWho this might be right forTreatment Efficacy Fudan University 400
Testing effectiveness (Phase 2)Ended earlyNCT02753595What this trial is testingStudy of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)Who this might be right forMetastatic Breast Cancer Eisai Inc. 25
Testing effectiveness (Phase 2)UnknownNCT03204734What this trial is testingCapecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast CancerWho this might be right forBreast Cancer Zhejiang Cancer Hospital 132
Not applicableNot Yet RecruitingNCT07389200What this trial is testingApplication of Multimodal MRI-based Radiomics in Histological Grading and Prognostic Assessment of Breast CancerWho this might be right forBreast CancerBreast Cancer With Low to Intermediate HER2 Expression Hao Xu 400
Not applicableNot Yet RecruitingNCT07198672What this trial is testingPrimary Prevention of Thrombocytopenia Associated With T-DM1 Therapy in HER2 Positive Breast Cancer With HerombopagWho this might be right forHER2-positive Breast Cancer Zhenzhen Liu 45
Not applicableStudy completedNCT05905939What this trial is testingHER2(Human Epidermal Growth Factor Receptor 2) -Positive Metastatic Breast Cancer in RussiaWho this might be right forBreast Cancer AstraZeneca 774
Testing effectiveness (Phase 2)Looking for participantsNCT07405801What this trial is testingA Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast CancerWho this might be right forBreast Cancer Hoffmann-La Roche 80
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07423611What this trial is testingCtDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast CancerWho this might be right forBreast Cancer Fudan University 388
Testing effectiveness (Phase 2)Study completedNCT01565083What this trial is testingAssess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast CancerWho this might be right forBreast Cancer Hoffmann-La Roche 213
Not applicableStudy completedNCT02670577What this trial is testingMeasuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective RegistryWho this might be right forBreast Cancer Agendia 481
Not applicableLooking for participantsNCT05396612What this trial is testingRole of the Immune Environment in Response to Therapy in Breast CancerWho this might be right forBreast CancerER Positive Breast CancerHER2-negative Breast Cancer+1 more Abramson Cancer Center at Penn Medicine 300
Testing effectiveness (Phase 2)Looking for participantsNCT04563507What this trial is testingCombined Immunotherapies in Metastatic ER+ Breast CancerWho this might be right forBreast Cancer Weill Medical College of Cornell University 102
Large-scale testing (Phase 3)Study completedNCT00333775What this trial is testingBevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast CancerWho this might be right forBreast Cancer Hoffmann-La Roche 736